An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)

Phase 2 Recruiting 20 enrolled Derm Texas, PLLC Arcutis Biotherapeutics, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

An open-label single center, proof of concept study evaluating the efficacy of Roflumilast foam 0.3% in pediatric subjects with Non-Segmental Vitiligo (NSV)

Timeline

Start: 2025-08-01
Primary completion: 2026-05-15
Completion: 2026-06-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Roflumilast	Small molecule	0.3 %	Topical

An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)

Summary

Timeline

Drugs

Indications